Changing paradigm in treatment of lung cancer

Changing paradigm in treatment of lung cancer Sundaram Viswanath, Abhishek Pathak, Amul Kapoor, Anvesh Rathore, Bhupendra Nath Kapur Medical Oncology, Army Hospital Research and Referral, New Delhi 110010, India. Correspondence to: Dr. Abhishek Pathak, Medical Oncology, Army Hospital Research and Referral, New Delhi 110010, India. E-mail: drabhipat@gmail.com Lung cancer is one of the most common and deadliest forms of cancer. It accounts for 13% of all new cancer cases and 19% of cancer-related deaths. In India, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer cases. There has also been a dramatic rise worldwide in both the absolute and relative frequencies of lung cancer occurrence. In 1953 it became the most common cause of cancer mortality in men. By 1985, it became the leading cause of cancer deaths in women, causing almost twice as many deaths as breast cancer. The demographic profile of lung cancer has changed greatly over the years; however, methods for diagnosing, screening, and managing lung cancer patients have improved. This is due to our growing understanding of the biology of lung cancer. It is now possible to further define lung cancer types beyond small cell lung carcinoma and non-small cell lung carcinoma. Moreover, new histology-based therapeutic modalities have been developed, and more new lung cancer biomarkers have been uncovered. Therefore, more detailed histological characterization of lung cancer samples is warranted in order to determine the best course of treatment for specific patients. This review article describes how these new molecular technologies are shaping the way lung cancer can be treated in future.